AI assistant
Pharnext — Investor Presentation 2017
Feb 7, 2017
1594_iss_2017-02-07_90062787-919d-4649-aadc-d444f1811493.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Press release
Pharnext to Present at 2017 BIO CEO & Investor Conference
PARIS, February 7, 2017 at 8:00am (CET) – Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today that company management will present a corporate overview at the 2017 BIO CEO & Investor Conference.
The presentation will take place as follows:
- Date: Monday, February 13th , 2017
- Time: 10:00 am ET (4:00 pm CET)
- Venue: The Waldorf Astoria in New York, New York.
If you are interested in meeting the Pharnext management team during this event, please send an email to Sarah McCabe at [email protected]
About Pharnext
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™ . The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
PHARNEXT | THE NEXT MEDICINE
CONTACTS:
Pharnext Pierre Schwich Chief Financial Officer [email protected] +33 (0)1 41 09 22 30
Investors Relations (Europe) MC Services AG Anne Hennecke [email protected] +49 211 529252 22
Media Relations (Europe) ALIZE RP Caroline Carmagnol Margaux Pronost [email protected] +33 (0)1 44 54 36 64
Investors Relations (U.S.)
Stern Investor Relations, Inc. Sarah McCabe [email protected] +1 212-362-1200
Media Relations (U.S.) Russo Partners Tony Russo, Ph.D. Victoria Meissner, M.D. [email protected] [email protected] +1 212-845-4251 +1 646-942-5627
Financial Communication (France) NewCap Julie Coulot [email protected] +33 (0)1 44 71 20 40